Get the Stockscreener App
14.82
0.41%
0.06
Carlsmed Inc stock is traded at $14.82, with a volume of 45,213.
It is up +0.41% in the last 24 hours and down -6.20% over the past month.
Carlsmed Inc is a commercial-stage medical technology company focused on developing AI-enabled personalized solutions for spine surgery. The company operates as a single operating and reportable segment engaged in the design, manufacture, and marketing of its Aprevo technology platform, which provides customized surgical planning and implants for lumbar and cervical spine fusion procedures, mainly sold to hospitals and ambulatory surgical centers.
See More
Previous Close:
$14.76
Open:
$14.7
24h Volume:
45,213
Relative Volume:
0.33
Market Cap:
$404.63M
Revenue:
$56.44M
Net Income/Loss:
$-32.60M
P/E Ratio:
-12.03
EPS:
-1.2318
Net Cash Flow:
$-35.15M
1W Performance:
-3.70%
1M Performance:
-6.20%
6M Performance:
+45.44%
1Y Performance:
+3.42%
1-Day Range:
$14.43
$14.93
1-Week Range:
$14.43
$15.88
52-Week Range:
$8.50
$17.23
Carlsmed Inc Stock (CARL) Company Profile
Name
Carlsmed Inc
Sector
Industry
Phone
858-295-9290
Address
1800 ASTON AVENUE, CARLSBAD
Compare CARL vs VEEV, TEM, BTSG, TXG, HNGE
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CARL
Carlsmed Inc
|
14.82 | 404.63M | 56.44M | -32.60M | -35.15M | -1.2318 |
VEEV
Veeva Systems Inc
|
274.84 | 44.50B | 3.32B | 941.65M | 1.64B | 5.6161 |
TEM
Tempus Ai Inc
|
82.24 | 14.93B | 1.36B | -302.91M | -219.93M | -1.7182 |
BTSG
Brightspring Health Services Inc
|
56.02 | 11.08B | 13.65B | 169.86M | 412.12M | 1.0758 |
TXG
10 X Genomics Inc
|
84.11 | 10.96B | 638.78M | -22.66M | 122.18M | -0.1744 |
HNGE
Hinge Health Inc
|
91.98 | 7.42B | 646.34M | -512.40M | 202.76M | -6.6871 |
Carlsmed Inc Stock (CARL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-18-25 | Initiated | BTIG Research | Buy |
| Aug-18-25 | Initiated | BofA Securities | Buy |
| Aug-18-25 | Initiated | Goldman | Buy |
| Aug-18-25 | Initiated | Piper Sandler | Overweight |
| Aug-18-25 | Initiated | Truist | Buy |
Carlsmed Inc Stock (CARL) Latest News
Carlsmed, Inc.(NasdaqGS: CARL) added to S&P Global BMI Index - marketscreener.com
Presidio Management Group XII buys $3m in Carlsmed stock By Investing.com - Investing.com Nigeria
Presidio Management Group XII buys $3m in Carlsmed stock - Investing.com
Carlsmed files patent lawsuit against DeGen Medical By Investing.com - Investing.com Australia
Carlsmed, Inc. Files Patent Infringement Lawsuit against DeGen Medical - The Manila Times
Carlsmed files patent lawsuit against DeGen Medical - Investing.com
Carlsmed Files Patent Infringement Lawsuit Against DeGen Medical Over Spine Surgery Technologies - Quiver Quantitative
Ten percent owner boosts stake in Carlsmed (CARL) - Stock Titan
Carlsmed, Inc. (NASDAQ:CARL) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Carlsmed COO Jeffrey Bertolini Awarded 50,000 Stock Options with $15.23 Exercise Price - Kalkine Media
Carlsmed (CARL) awards COO 50,000 stock options - Stock Titan
Carlsmed (CARL) COO discloses 22,489-share stake - Stock Titan
Carlsmed, Inc. Announces Chief Operating Officer Appointment - The Manila Times
Carlsmed, Inc.: Shareholders Board Members Managers and Company Profile | US14280C1053 - marketscreener.com
Carlsmed appoints Jeff Bertolini as new COO - TipRanks
Carlsmed names Jeffrey Bertolini as Chief Operating Officer - TradingView
symbol__ Stock Quote Price and Forecast - cnn.com
BlackRock Inc. Purchases New Holdings in Carlsmed, Inc. $CARL - MarketBeat
Jupiter Topco LLC Acquires New Holdings in Carlsmed, Inc. $CARL - MarketBeat
Wall Street Analysts Think Carlsmed, Inc. (CARL) Could Surge 90.77%: Read This Before Placing a Bet - qz.com
Parkman Healthcare Partners LLC Invests $6.20 Million in Carlsmed, Inc. $CARL - MarketBeat
Carlsmed (CARL) Earnings Snapshot: EPS Lands Above Forecast on the Day; The Stock Ends Down 1.56% in the Current UpdateEPS Surprise History - dars.gov.et
Carlsmed, Inc. (NASDAQ:CARL) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Wall Street Zen Upgrades Carlsmed (NASDAQ:CARL) to "Hold" - MarketBeat
Carlsmed (CARL) plans up to $250M in stock, debt and warrant sales - Stock Titan
Carlsmed (CARL) Holds Steady Near $13.72 as Tight Range Signals Potential MoveDefined Outcome ETF - vinanet.vn
Carlsmed Eyes Growth as Cervical Launch, Medicare Shift Boost Spine Platform - TradingView
Transcript : Carlsmed, Inc. Presents at Bank of America SMID Cap Virtual Conference, Aug-12-2026 11 - marketscreener.com
CARL: Personalized AI spine surgery platform accelerates growth with new reimbursement and strong clinical data - TradingView
Carlsmed, Inc. Common Stock (NASDAQ: CARL) Share Price, CARL Stock News, CARL Share Price & Updates - Kalkine
Carlsmed, Inc. (NASDAQ: CARL) Share Price, CARL Stock News, CARL Share Price & Updates - kalkine.ca
Truist raises Carlsmed stock price target on strong growth outlook By Investing.com - Investing.com South Africa
Carlsmed Buy Rating Reaffirmed as 2026 Outlook Raised and Adoption Grows; $17 Price Target Maintained - TipRanks
Analysts Are Bullish on These NA Stocks: BillionToOne, Inc. Class A (BLLN), Carlsmed, Inc. (CARL) - The Globe and Mail
Carlsmed Q2 2026 revenue up 57% to USD 18.9M - Medical Buyer
Truist raises Carlsmed stock price target on strong growth outlook - Investing.com Nigeria
CARLSMED INC Q2 NET INCOME USD -10.5 MILLION - Moomoo
Truist Adjusts Price Target on Carlsmed to $20 From $18, Maintains Buy Rating - marketscreener.com
Carlsmed, Inc. Stock 12‑Month Price Target Raised to $19.2, Implies 42% Upside - TradingView
Carlsmed Inc. (CARL) Advances 4.79% to $14.21: Personalized Spine Tech Gains TractionHigh Reward Trades - dars.gov.et
Carlsmed Inc (CARL) (Q2 2026) Earnings Call Highlights: Revenue Surges 57% to $18. ... - Yahoo Finance UK
Carlsmed Q2 Earnings Call Highlights - Yahoo Finance
Carlsmed, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Carlsmed, Inc. (CARL) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
CARLSMED, INC. Q2 2026: Revenue $18.94M, EPS $(0.39) — 10-Q Summary - TradingView
Carlsmed reports Q2 2026 revenue $18.9M, raises full-year guidance to $74–$78M - TradingView
Carlsmed® Reports Second Quarter 2026 Financial Results and Raises Full-Year Guidance - The Manila Times
Carlsmed, Inc. Raises Earnings Guidance for the Fiscal Year 2026 - marketscreener.com
Carlsmed, Inc. $CARL Stock Holdings Lifted by Janus Henderson Group PLC - MarketBeat
Carlsmed (CARL) Earnings Date and Reports 2026 $CARL - MarketBeat
Carlsmed (CARL) Gains Favorable CMS Reimbursement Policy Boostin - GuruFocus
Carlsmed Inc Stock (CARL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Carlsmed Inc Stock (CARL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Cordonnier Michael | CEO, President |
Mar 02 '26 |
Option Exercise |
0.34 |
197,855 |
66,281 |
1,554,501 |
| Cordonnier Michael | CEO, President |
Mar 02 '26 |
Sale |
13.29 |
197,855 |
2,629,889 |
1,356,646 |
0.07%
2.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):